Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Analyst Ratings Changes
SRPT has been the subject of several analyst reports. The Goldman Sachs Group cut their target price on Sarepta Therapeutics from $181.00 to $155.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th. Credit Suisse Group raised their target price on Sarepta Therapeutics from $90.00 to $93.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 3rd. Morgan Stanley lifted their price target on Sarepta Therapeutics from $80.00 to $100.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 3rd. Oppenheimer lifted their price target on Sarepta Therapeutics from $125.00 to $150.00 in a research report on Wednesday, August 3rd. Finally, Cantor Fitzgerald dropped their price target on Sarepta Therapeutics from $140.00 to $128.00 and set an "overweight" rating for the company in a research report on Friday, June 24th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $128.62.
Sarepta Therapeutics Price Performance
Shares of NASDAQ:SRPT traded down $2.37 during trading hours on Tuesday, reaching $109.10. 1,999,428 shares of the stock traded hands, compared to its average volume of 921,353. The company has a market capitalization of $9.55 billion, a P/E ratio of -18.59 and a beta of 1.27. The company has a quick ratio of 4.14, a current ratio of 4.53 and a debt-to-equity ratio of 1.52. Sarepta Therapeutics has a 52-week low of $61.28 and a 52-week high of $112.89. The company's 50-day simple moving average is $79.69 and its two-hundred day simple moving average is $77.32.